• SPX
  • $5,969.34
  • 0.35 %
  • $20.63
  • DJI
  • $44,296.51
  • 0.97 %
  • $426.16
  • N225
  • $38,283.85
  • 0.68 %
  • $257.68
  • FTSE
  • $8,262.08
  • 1.38 %
  • $112.81
  • IXIC
  • $19,003.65
  • 0.16 %
  • $31.23
Tenaya Therapeutics, Inc. (TNYA) Stock Price, News & Analysis

Tenaya Therapeutics, Inc. (TNYA) Stock Price, News & Analysis

Currency in USD Disclaimer

$2.38

$0.22

(10.19%)

Day's range
$2.1
Day's range
$2.39
50-day range
$1.61
Day's range
$3.13
  • Country: US
  • ISIN: US87990A1060
52 wk range
$1.61
Day's range
$7.01


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -3.03
  • Piotroski Score 2.00
  • Grade Buy
  • Symbol (TNYA)
  • Company Tenaya Therapeutics, Inc.
  • Price $2.38
  • Changes Percentage (10.19%)
  • Change $0.22
  • Day Low $2.10
  • Day High $2.39
  • Year High $7.01

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) caused by haploinsufficient myosin binding protein C3 (MYBPC3) gene mutations; and TN-301, a small molecule inhibitor of histone deacetylase 6 (HDAC6i) for use in heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM). It is also developing TN-401, an AAV-based gene therapy that addresses genetic arrhythmogenic right ventricular cardiomyopathy (gARVC) caused by plakophilin 2 (PKP2) gene mutations; an AAV-based gene therapy designed to deliver the dwarf open reading frame (DWORF) gene in the heart for DCM; and Reprogramming program, an AAV-based approach for cardiac regeneration to replace heart cells lost in patients experiencing heart failure due to prior myocardial infarction. The company was incorporated in 2016 and is headquartered in South San Francisco, California.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 03/17/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $0.00
  • High Stock Price Target $0.00
  • Low Stock Price Target $0.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$1.65
  • Trailing P/E Ratio -2.21
  • Forward P/E Ratio -2.21
  • P/E Growth -2.21
  • Net Income $-124,084,000

Income Statement

Quarterly

Annual

Latest News of TNYA

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Tenaya Therapeutics, Inc. Frequently Asked Questions

  • What were the earnings of TNYA in the last quarter?

    In the last quarter Tenaya Therapeutics, Inc. earnings were on Wednesday, November, 6th. The Tenaya Therapeutics, Inc. maker reported -$0.30 EPS for the quarter, beating analysts' consensus estimates of -$0.37 by $0.07.

  • What is the Tenaya Therapeutics, Inc. stock price today?

    Today's price of Tenaya Therapeutics, Inc. is $2.38 — it has increased by +10.19% in the past 24 hours. Watch Tenaya Therapeutics, Inc. stock price performance more closely on the chart.

  • Does Tenaya Therapeutics, Inc. release reports?

    Yes, you can track Tenaya Therapeutics, Inc.'s financials in yearly and quarterly reports directly on Stocks.News.

  • What is the Tenaya Therapeutics, Inc. stock forecast?

    Watch the Tenaya Therapeutics, Inc. chart and read a more detailed Tenaya Therapeutics, Inc. stock forecast to see what analysts suggest you do with its shares.

  • What is Tenaya Therapeutics, Inc. stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by Tenaya Therapeutics, Inc. stock ticker.

  • How to buy Tenaya Therapeutics, Inc. stocks?

    Like other stocks, TNYA shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is Tenaya Therapeutics, Inc.'s EBITDA?

    Tenaya Therapeutics, Inc. measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in Tenaya Therapeutics, Inc.’s financial statements.

  • What is the Tenaya Therapeutics, Inc.'s net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is 0, which equates to approximately 0.00%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in Tenaya Therapeutics, Inc. stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including Tenaya Therapeutics, Inc.'s financials relevant news, and technical analysis. Tenaya Therapeutics, Inc.'s technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for Tenaya Therapeutics, Inc. stock currently indicates a “sell” signal. For more insights, review Tenaya Therapeutics, Inc.’s technical analysis.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.